M6-Lecture3 Flashcards
agents that cause non-heritable birth defects.
Teratogens
2-5% born with abnormalities
testing is expensive
See diagram
Wilson’s Principles of teratology
Susceptibility to the teratogenic effect of an agent depends on
on the genotype of the embryo
the genotype of the mother,
and the ways in which their genotypes allow mother and fetus to interact
Wilson’s Principles of teratology
Teratogenic agents act in specific ways on genes, cells and tissues
Interfere with normal development
The placenta does not completely protect the fetus as is seen with Rubella infections during the 1st trimester.
Wilson’s Principle here emphasizes that while the placenta offers some protection, it is not a perfect barrier, and certain infections or teratogens can still harm the fetus, especially during sensitive periods of development like the first trimester.
Wilson’s Principles of teratology
Several factors affect the ability of a teratogen to interfere with normal development.
Include the nature of the agent, the route and degree of maternal exposure, ability of mother to detoxify or block the agent, rate of transfer through the placenta, the rate of absorption by the embryo or fetus, and the genotype of the mother and her conceptus.
Wilson’s Principles of teratology
There are four major manifestations of abnormal development
death, malformation, growth retardation, and functional defects
Wilson’s principles of teratology
As teratogen dose increase, abnormal development increase in frequency an degree
Teratogenesis - definitions
Congenital anomaly – birth defect- can be structural or functional
Functional = intellectual (cognitive), emotional physiological
Structural = malformations, disruptions, deformations or dysplasias
Malformation – failure of tissue to initially form properly.
Disruption – Breakdown of a tissue that has initially formed properly.
Deformation- extrinsic mechanical forces on otherwise normal tissue.
Dysplasia – A lack of normal organization of cells in a tissue
Most teratogens produce structural defects only during certain critical periods of development.
Embryonic period – Conception to 8 weeks
Fetal period – remaining time in utero
Rare to have congenital anomalies before 3 weeks because teratogens damage either too many cells and it dies or too few cells and it recovers (pluripotent cells).
Pluripotent stem cells can differentiate into almost any cell type in the body, while multipotent stem cells can differentiate into a limited range of related cell types; totipotent stem cells can form all cell types, including extra-embryonic tissues, and unipotent stem cells can only produce one cell type, but retain the ability for self-renewal.
Maximum susceptibility is between 3-8 weeks when organs start to form. Except for CNS which forms continuously until adolescence.
teratogens can still be harmful even after organogenesis is complete, as exposure may lead to functional defects, growth issues, or long-term health problems. However, the risk of causing major congenital anomalies is lower after the organ has fully developed, as the critical periods of rapid development and differentiation have passed.
See diagram
Types of teratogens
Drugs & chemicals (thalidomide, mercury, alcohol, retionic acid)
Ionizing radiation (x-rays)
Hyperthermia (fever)
Infectious microorganisms
Mother’s Metabolic conditions
Mechanical forces
Thalidomide is a drug that was developed in the 1950s by the West German pharmaceutical company Chemie Grünenthal GmbH.
originally intended as a sedative or tranquiliser
For treating colds, flu, nausea and morning sickness in pregnant women.
But in 1960s was found to cause congenital mal.
Thalidomide
Why the delay:
Due to wide range of changes to fetal development that included Limbs, internal organs including the brain, eyesight andhearingcould all be affected.
Some of its damaged resembled certain genetic conditions that affect the upper or lower limbs.
It did not show teratogenic effects in rodents.
Thalidomide effects:
Phocomelia, along with a range of severe birth defects including disfigurements, ocular abnormalities, facial palsies, internal organ damage, congenital heart disease, and an increased risk of miscarriages, was caused by thalidomide, a teratogen that affected over 7,000 infants when taken between days 20-36 of pregnancy.
Thalidomide is a very complex molecule, requiring metabolic breakdown to achieve activity and forming potentially over 100 by-products
The major functions of these by-products are anti-inflammatory, immunomodulatory, sedative or anti-angiogenic
These by-products can interfere with the normal formation of blood vessels, which are crucial for the paracrine signaling pathways needed for limb bud development, ultimately leading to teratogenic effects such as phocomelia.
In angiogenesis, proteases break down extracellular matrix components to allow cell migration, while migrating cells proliferate to form vascular tubes that mature into functional blood vessels.
When thalidomide is metabolized, it produces both potentially harmful (teratogenic) and harmless (non-teratogenic) metabolites
once smooth muscle cells cover the newly formed blood vessels, thalidomide no longer has an impact.
thalidomide also has immunosuppressive properties, inhibiting the release of pro-inflammatory molecules like tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) from immune cells, further contributing to its broad range of effects.
IGF-1 (Insulin-like Growth Factor 1) and FGF-2 (Fibroblast Growth Factor 2) are signaling molecules that play key roles in cell growth, survival, and development. They can stimulate the expression of certain genes involved in angiogenesis (the formation of blood vessels).
These signaling molecules (IGF-1 and FGF-2) activate the transcription (the process of making RNA from DNA) of the genes that code for two subunits: αv and β3 } form dimerization and then are involved in blood vessel formation.
Thalidomide disrupts this process.